checkmate 9la | First-line nivolumab plus ipilimumab combined with two

Keyword	CPC	PCC	Volume	Score	Length of keyword
checkmate 9la	0.21	1	6012	30	13
checkmate	1.63	0.2	9658	71	9
9la	0.3	0.4	8218	66	3

Keyword	CPC	PCC	Volume	Score
checkmate 9la	0.89	0.4	9547	28
checkmate 9la regimen	0.13	0.9	6021	42
checkmate 9la trial	0.27	0.7	7647	25
checkmate 9la nejm	1.74	0.7	8012	90
checkmate 9la schema	1.58	0.4	9046	52
checkmate 9la update	0.47	0.1	5865	82
checkmate 9la 3 year update	1.39	0.2	2858	31
checkmate 9la protocol	1.61	0.2	4788	64
checkmate 9la asco	0.04	1	8691	21
checkmate 9la studie	1.54	0.7	7864	35
checkmate 9la 3 year	1.47	0.4	9298	79
checkmate 9la study	1.1	0.6	301	86
checkmate 9la pubmed	1.03	0.4	5897	8
checkmate 9la approval	2	0.5	6487	54

Search Results related to checkmate 9la on Search Engine

First-line nivolumab plus ipilimumab combined with two cycles of
thelancet.com

https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30641-0/fulltext

WEBJan 18, 2021 · Results from CheckMate 9LA have shown that PD-L1 expression was not predictive of improved survival because the magnitude of benefit with nivolumab plus ipilimumab with a limited course of chemotherapy versus chemotherapy alone was consistent across all PD-L1 expression levels assessed.

DA: 73 PA: 24 MOZ Rank: 35

First-Line Nivolumab Plus Ipilimumab With Chemotherapy Versus
jto.org

https://www.jto.org/article/S1556-0864(22)01864-0/fulltext

WEBOct 28, 2022 · In the phase 3 CheckMate 9LA study, nivolumab plus ipilimumab with chemotherapy prolonged overall survival (OS) versus chemotherapy alone. We report updated efficacy and safety (≥3 y of follow-up), clinical outcomes in patients with baseline brain metastases, and exploratory somatic mutation analyses.

DA: 88 PA: 54 MOZ Rank: 39

First-line (1L) nivolumab (N) + ipilimumab (I) + chemotherapy (C) …
ascopubs.org

https://ascopubs.org/doi/10.1200/JCO.2023.41.17_suppl.LBA9023

WEBJun 7, 2023 · First-line (1L) nivolumab (N) + ipilimumab (I) + chemotherapy (C) vs C alone in patients (pts) with metastatic NSCLC (mNSCLC) from CheckMate 9LA: 4-y clinical update and outcomes by tumor histologic subtype (THS). | Journal of Clinical Oncology.

DA: 36 PA: 16 MOZ Rank: 9

First-line nivolumab plus ipilimumab combined with two cycles of
nih.gov

https://pubmed.ncbi.nlm.nih.gov/33476593/

WEBFirst-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2021 Feb;22 (2):198-211. doi: 10.1016/S1470-2045 (20)30641-0. Epub 2021 Jan 18.

DA: 44 PA: 79 MOZ Rank: 34

First-line nivolumab plus ipilimumab with two cycles of ... - PubMed
nih.gov

https://pubmed.ncbi.nlm.nih.gov/34607285/

WEBFirst-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update. ESMO Open. 2021 Oct;6 (5):100273. doi: 10.1016/j.esmoop.2021.100273. Epub 2021 Oct 1.

DA: 63 PA: 95 MOZ Rank: 99

First-line nivolumab (NIVO) plus ipilimumab (IPI) plus two cycles …
ascopubs.org

https://ascopubs.org/doi/10.1200/JCO.2021.39.15_suppl.9000

WEBMay 28, 2021 · First-line nivolumab (NIVO) plus ipilimumab (IPI) plus two cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients with advanced non-small cell lung cancer (NSCLC): Two-year update from CheckMate 9LA. | Journal of …

DA: 20 PA: 41 MOZ Rank: 12

First-line nivolumab plus ipilimumab with two cycles of ... - PubMed
nih.gov

https://pubmed.ncbi.nlm.nih.gov/36871487/

WEBFirst-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomes. Eur J Cancer. 2023 Apr:183:174-187. doi: 10.1016/j.ejca.2023.01.015. Epub 2023 Jan 28.

DA: 100 PA: 16 MOZ Rank: 87

First-line nivolumab plus ipilimumab with two cycles of …
esmoopen.com

https://www.esmoopen.com/article/S2059-7029(21)00235-0/fulltext

WEBOct 1, 2021 · CheckMate 9LA (NCT03215706) is a randomized phase III study evaluating nivolumab plus ipilimumab combined with a limited course of chemotherapy (two cycles) versus chemotherapy alone (four cycles) as a first …

DA: 17 PA: 57 MOZ Rank: 94

First-line nivolumab plus ipilimumab combined with two cycles of
nih.gov

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8956544/

WEBFeb 19, 2022 · CheckMate 9LA (NCT03215706), a phase 3, randomized, open-label study in first-line advanced NSCLC, showed significantly improved overall survival (OS), progression-free survival (PFS), and objective response rate (ORR) with nivolumab plus ipilimumab combined with 2 cycles of chemotherapy versus 4 cycles of chemotherapy …

DA: 27 PA: 21 MOZ Rank: 90

Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung …
nejm.org

https://www.nejm.org/doi/full/10.1056/NEJMoa1910231

WEBSep 28, 2019 · First-line nivolumab plus ipilimumab in advanced non-small-cell lung cancer (CheckMate 568): outcomes by programmed death ligand 1 and tumor mutational burden as biomarkers.

DA: 1 PA: 17 MOZ Rank: 77